Dennis Slamon

Dennis Joseph Slamon (born August 6, 1948), is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.

He currently serves as director of Clinical/Translational Research at UCLA's Jonsson Comprehensive Cancer Center, and as director of the Revlon/UCLA Women's Cancer Research Program at JCCC. He is a professor of medicine, chief of the Division of Hematology/Oncology and executive vice chair for research for UCLA's Department of Medicine. Slamon also serves as director of the medical advisory board for the National Colorectal Cancer Research Alliance, a fund-raising organization that promotes advances in colorectal cancer. Provided by Wikipedia
Showing 1 - 7 results of 7 for search 'Dennis J. Slamon', query time: 0.03s Refine Results
  1. 1
    Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.

    Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy. by Jason J Zoeller, Michael F Press, Laura M Selfors, Judy Dering, Dennis J Slamon, Sara A Hurvitz, Joan S Brugge

    Published 2021-01-01
    Get full text
    Article
  2. 2
    Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient

    Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient by Nu T. Lu, Jeffrey Raizer, Erwin P. Gabor, Natalie M. Liu, James Q. Vu, Dennis J. Slamon, John L. Barstis

    Published 2015-09-01
    Get full text
    Article
  3. 3
    Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

    Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III stu... by Sanne L. de Haas, Dennis J. Slamon, Miguel Martin, Michael F. Press, Gail D. Lewis, Chiara Lambertini, Aleix Prat, Vanesa Lopez-Valverde, Thomas Boulet, Sara A. Hurvitz

    Published 2023-01-01
    Get full text
    Article
  4. 4
    Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

    Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy by Martina S. J. McDermott, Brigid C. Browne, Neil T. Conlon, Neil A. O’Brien, Dennis J. Slamon, Michael Henry, Paula Meleady, Martin Clynes, Paul Dowling, John Crown, Norma O’Donovan

    Published 2023-10-01
    Get full text
    Article
  5. 5
    A careful reassessment of anthracycline use in curable breast cancer

    A careful reassessment of anthracycline use in curable breast cancer by Sara Alsterlind Hurvitz, Nicholas P. McAndrew, Aditya Bardia, Michael F. Press, Mark Pegram, John P. Crown, Peter A. Fasching, Bent Ejlertsen, Eric H. Yang, John A. Glaspy, Dennis J. Slamon

    Published 2021-10-01
    Get full text
    Article
  6. 6
    Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies

    Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies by Maggie Chon U Cheang, Mothaffar Rimawi, Stephen Johnston, Samuel A. Jacobs, Judith Bliss, Katherine Pogue-Geile, Lucy Kilburn, Zhou Zhu, Eugene F. Schuster, Hui Xiao, Lisa Swaim, Shibing Deng, Dongrui R. Lu, Eric Gauthier, Jennifer Tursi, Dennis J. Slamon, Hope S. Rugo, Richard S. Finn, Yuan Liu

    Published 2024-06-01
    Get full text
    Article
  7. 7
    Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy endocrine therapy alone in patients with HR+/HER2− early breast cancer

    Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy endocrine therapy alone in patients with HR+/HER2− early breast cancer by Dennis J. Slamon, Peter A. Fasching, Sara Hurvitz, Stephen Chia, John Crown, Miguel Martín, Carlos H. Barrios, Aditya Bardia, Seock-Ah Im, Denise A. Yardley, Michael Untch, Chiun-Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca L. Moroose, Sherene Loi, Frances Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N. Hortobagyi

    Published 2023-05-01
    Get full text
    Article

Search Tools: